Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Leuprolide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 2/20 | 0.72 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.74 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.66 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.59 |
| ▸ | APLNR | P35414 | 4/20 | 0.56 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leuprolide SCHEMBL1357405 | 1.00 | ABCC2 (0.74) | ABCC2GNRHRPTGS1C5AR1APLNR | |
| Acetic Acid SCHEMBL28807132 | 1.00 | ABCC2 (0.74) | ABCC2GNRHRPTGS1C5AR1APLNR | |
| Deslorelin SCHEMBL205614 | 1.00 | ABCC2 (0.74) | ABCC2GNRHRPTGS1C5AR1APLNR | |
| Acetic Acid SCHEMBL5166423 | 1.00 | ABCC2 (0.74) | ABCC2GNRHRPTGS1C5AR1APLNR | |
| Leuprolide SCHEMBL1654929 | 1.00 | ABCC2 (0.74) | ABCC2GNRHRPTGS1C5AR1APLNR | |
| Leuprolide SCHEMBL22288711 | 1.00 | ABCC2 (0.74) | ABCC2GNRHRPTGS1C5AR1APLNR | |
| Leuprolide SCHEMBL27849465 | 0.99 | ABCC2 (0.73) | ABCC2GNRHRPTGS1C5AR1APLNR | |
| Leuprolide SCHEMBL25418953 | 0.99 | GNRHR (0.74) | ABCC2GNRHRPTGS1C5AR1APLNR | |
| Deslorelin SCHEMBL59413 | 0.99 | GNRHR (0.74) | ABCC2GNRHRPTGS1C5AR1APLNR | |
| Leuprolide SCHEMBL172917 | 0.99 | GNRHR (0.74) | ABCC2GNRHRPTGS1C5AR1APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 760 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069700-A1 | BRUSH PRODRUGS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-03-12 | — | — | US | claimed |
| US-20260034101-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC INC (US) | 2026-02-05 | — | — | US | claimed |
| US-12383533-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2025-08-12 | — | — | US | claimed |
| WO-2025111447-A1 | TREATMENT OF CANCER WITH DRUG COMBINATIONS | FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES (US) | 2025-05-30 | — | — | WO | claimed |
| CN-119677539-A | Combination therapy for modulating lipid production | 俄亥俄州创新基金会 | 2025-03-21 | — | — | CN | claimed |
| EP-4489865-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | Ohio State Innovation Foundation (US) | 2025-01-15 | — | — | EP | claimed |
| EP-4433462-A1 | USP9X INHIBITORS | Prodeg, LLC (US) | 2024-09-25 | — | — | EP | claimed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | claimed |
| WO-2023172669-A9 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION (US) | 2024-08-02 | — | — | WO | claimed |
| US-11998606-B2 | Compounds and methods for selective proteolysis of glucocorticoid receptors | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-06-04 | — | — | US | claimed |
| WO-2023172669-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-14 | — | — | WO | claimed |
| EP-4196133-A2 | METHODS AND COMPOSITIONS FOR STIMULATING GAMMA DELTA T CELLS | University of Central Florida Research Foundation, Inc. (US) | 2023-06-21 | — | — | EP | claimed |
| WO-2023091464-A1 | USP9X INHIBITORS | ProDeg, LLC (US) | 2023-05-25 | — | — | WO | claimed |
| WO-2023089601-A2 | USP9X INHIBITORS | ProDeg, LLC (US) | 2023-05-25 | — | — | WO | claimed |
| US-20220370628-A9 | BRUSH PRODRUGS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-11-24 | — | — | US | claimed |
| US-20220275094-A1 | Method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases | MERCK PATENT GMBH (DE) | 2022-09-01 | — | — | US | claimed |
| EP-4045562-A2 | BRUSH PRODRUGS AND USES THEREOF | Massachusetts Institute of Technology (US) | 2022-08-24 | — | — | EP | claimed |
| US-11306146-B2 | Method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases | MERCK PATENT GMBH (DE) | 2022-04-19 | — | — | US | claimed |
| WO-2022036024-A9 | METHODS AND COMPOSITIONS FOR STIMULATING GAMMA DELTA T CELLS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2022-04-07 | — | — | WO | claimed |
| WO-2022036024-A2 | METHODS AND COMPOSITIONS FOR STIMULATING GAMMA DELTA T CELLS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2022-02-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034101-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | NCOR1, NR0B1, NCOR2 | GNRHR 66/4885ABCC2 338/4885PTGS1 3303/4885 |
| US-12383533-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | CCNA1, CCNE1, CCNB1 | GNRHR 361/4885ABCC2 684/4885PTGS1 2582/4885 |
| US-11998606-B2 | Compounds and methods for selective proteolysis of glucocorticoid receptors | NR3C1, NR3C2, GRK5 | GNRHR 99/4885ABCC2 4547/4885PTGS1 435/4885 |
| US-20220370628-A9 | BRUSH PRODRUGS AND USES THEREOF | ABCB11, SI, ABCB1 | GNRHR 3014/4885ABCC2 721/4885PTGS1 2895/4885 |
| US-20260069700-A1 | BRUSH PRODRUGS AND USES THEREOF | ABCB11, SLC10A2, CES2 | GNRHR 2198/4885ABCC2 154/4885PTGS1 2670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.